peptide analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Superacids can permanently protonate water to give ionic, crystalline hydronium "salts". They can also quantitatively stabilize carbocations. While Ka measures the strength of an acid compound, the strength of an aqueous acid solution is measured by pH, which is an indication of the concentration of hydronium in the solution. The pH of a simple solution of an acid compound in water is determined by the dilution of the compound and the compound's Ka.
Task Force 1–41 Infantry was the first coalition force to breach the Saudi Arabian border on 15 February 1991 and conduct ground combat operations in Iraq engaging in direct and indirect fire fights with the enemy on 17 February 1991. Prior to this action the Task Force's primary fire support battalion, 4th Battalion of the 3rd Field Artillery Regiment, participated in a massive artillery preparation. Around 300 guns from multiple countries participated in the artillery barrage. Over 14,000 rounds were fired during these missions. M270 Multiple Launch Rocket Systems contributed an additional 4,900 rockets fired at Iraqi targets. Iraq lost close to 22 artillery battalions during the initial stages of this barrage, including the destruction of approximately 396 Iraqi artillery pieces. By the end of these raids Iraqi artillery assets had all but ceased to exist. One Iraqi unit that was totally destroyed during the preparation was the Iraqi 48th Infantry Division Artillery Group. The group's commander stated his unit lost 83 of its 100 guns to the artillery preparation. The artillery bombardment was supplemented by Boeing B-52 Stratofortress bombing raids and Lockheed AC-130 attacks. AH-64 Apache attack helicopters from the 1st Infantry Division and B-52 bombers attacked the Iraqi 110th Infantry Brigade. Under enemy fire, the 1st and 9th Engineer Battalions marked and proofed assault lanes to secure a foothold in enemy territory and pass the 1st Infantry Division and the 1st Armoured Division forward.
=== Technology === Building on the foundational principles of ELISA, eSimoa employs paramagnetic beads to isolate biomolecules or enzymes in a manner akin to ELISA's plate-based detection. However, eSimoa advances this concept by enabling enzymatic reaction measurements at the single-molecule level, which dramatically improves detection limits for various enzymes and biomolecules. This method allows for the precise quantification of low-abundance proteins and the activity of critical enzymes such as protein kinases and telomerases, which are often below the detection threshold of conventional ELISA.
== Technology == CIM monoliths are made of porous methacrylate polymers composed of interconnected channels that range in size from 1-6 μm. It is these channels that account for the media separation power and flow characteristics and ability to purify large biomolecules, such as large proteins, immunoglobulins, plasmid DNA and viruses with their activity intact. Components to be separated are conveyed to the active groups located on the surface of the channels by bulk flow of the mobile phase. Since the channels are interconnected, there is no diffusion, no dead end pores, no void volume and no stagnant zones to slow down the transport between the stationary and mobile phase. Consequently, monolithic columns have flow independent resolution and binding capacity. They exhibit low back pressure, even at very high flow rates. In this way, the purification time can be significantly decreased, resulting in a pronounced reduction of the purification process costs.
Directed by Sheila Hayman, made by Uden Associates 8 November Rebuilding Berlin, how German telecommunication and electrical engineers found great difficulty in connecting the infrastructure and technology of East and West Berlin, which were largely totally incompatible, and why the two technological systems were so different; East and West Germany were founded in 1953; the trains in East (Deutsche Reichsbahn or DR) and West Germany ran on electric motors that worked in opposite ways; Erich Kratky of Berliner Verkehrsbetriebe (former West Berlin Public Transport) and how East Berlin drivers had 60% of those in West Berlin; Mahlow station, on the S2 line on the Berlin S-Bahn, was completely rebuilt in 1991, opening on 31 August 1992; before 1989, West Berlin could not connect to any neighbouring electrical power networks, so had to make all of its own power itself, by nine power stations; in 1992 West Berlin could not make enough electrical power;Jürgen Beyer of the East Berlin Electricity Board; in 1992 East and West Germany could not connect their electricity systems together; Klaus Krämer of the West Berlin Electricity Board, and how East German load frequency control (LFC) was not good enough for West Germany; East German power stations were polluting; Müggelsee in East Berlin; East Berlin had natural gas - from Russia - but West Berlin did not have natural gas, and had to produce its own gas from processing, and there were many more gas leaks in East Berlin, run by the Berlin Gas Board, and British Gas plc was installing most of the new plastic gas mains in East Berlin; one fifth of housing in East Berlin was uninhabitable, due to lack of renovation and unsafe electrical wiring; much housing in East Berlin did not have any bathrooms; the post system in East Berlin was three times slower than West Berlin, as it was all sorted by hand, and mail hand to be sent in standard envelopes only, in East Germany - the two post systems were incompatible, and East and West Germany had totally different postcode systems, although both had four digits, so a letter was put in front of each Deutsche Post postcode, to show if it was an East or West German postcode; in 1952, telephone connections between East and West Germany were stopped, but four lines were installed in 1972; the East German telephone exchanges were all mechanical, and could not transmit any digital communications; one in ten people in East Berlin had a phone - telecommunications in East Berlin were hopeless and expensive; in 1992 Deutsche Telekom connected East and West Berlin, and the price would be a local call, not the price of an international call, under the phrase Wir schaffen Verbingdungen; not only were East German telecommunications often impossible, but the Stasi secret police were listening in to most calls; Rudolf Reichel of the former East German Economic Institute; science research in East Germany had been greatly restricted; Volker Hassemer; East Germans viewed West Germans as selfish, and West Germans viewed East Germans as backward. Narrated by Su-Lin Looi, directed by Cosima Dannoritzer, produced by Karl Sabbagh, made by Skyscraper Productions 15 November 21st Century Jet, how the Boeing 777 moved from the drawing board to manufacture in 1992, with the innovative new method called CATIA; the Boeing 777 was the largest jet aircraft to have been developed mostly by computer, with assembly beginning in January 1993; there were 10,000 people in the 777 programme, who met the managers in a weekly meeting; meeting the needs of Robert Crandall of American Airlines, and competition from the new Airbus A340; parts of the tail were built in Australia; the nose cone and flaps were made in Italy; the landing gear was made in Canada, the US, and France; parts of the wing ribs and passenger doors were made in Japan; the nose landing gear door was made in Belfast; some of the electronics was made in England; there were about 230 design teams, from different manufacturers; the CATIA system was a digital mockup; Thomas Gaffney, head of passenger doors; Henry Shomber, one of the chief engineers; John Roundhill, a chief project engineer; United Airlines placed the first order, which started the project; Al Tyler of Aerospace Technologies of Australia (ASTA), who made the 777 rudder - the company became Boeing Australia; John King, Baron King of Wartnaby of British Airways visits to look at legroom for the new 777. Narrated by Simon Prebble, directed by Karl Sabbagh, made by Skyscraper Productions 22 November The Puzzle of HIV, scientists after ten years did not understand how HIV worked; immunologists Anthony Fauci and Max Essex; Angus Dalgleish of St George's, University of London; virologist Stephen S. Morse, and the origination of viruses, and how most pandemics originated in China; Stella Knight of the MRC, and dendritic cells, researched by Brigid Balfour; French immunologist Jean-Claude Ameisen of the Pasteur Institute of Lille; virologist Jonas Salk; Claude Nicolau, and the CD4 glycoprotein. Narrated by Scottish actress Sandra Clark, directed by Nigel Maslin, produced by Chris Haws, made by InCA Productions 29 November The Alpha Link, much of medical understanding of radiation protection and health comes from what occurred in Japan in August 1945. Martin Gardner (1940–93), an epidemiologist, and Professor of Medical Statistics at the University of Southampton, thought that health was affected by working in a nuclear power station, which the British nuclear industry vehemently would not believe. Directed by Vivienne King, made by Box Productions 6 December Toying with the Future, about electronic children's toys, visiting Ocean Software in Manchester; Brian Sutton-Smith of the University of Pennsylvania, and how toys were small replicas of large world events; Eugene F. Provenzo of the University of Miami and how the culture of childhood began in the early 1700s, and how German Friedrich Fröbel developed educational toys in the early 1800s, but it often lacked fun; Meccano Ltd sets, developed by Frank Hornby, launching the international Meccano Guild network of children's mechanical clubs in 1919, publicised by the Meccano Magazine; Richard Gregory, neuropsychologist at the University of Bristol, and his Exploratory Hands-on Science Centre, which closed in 1999, replaced by We the Curious in 2000; toy designer Patrick Rylands; Gary Bracey of Ocean Software; Keith Tinman, computer game musician; Elizabeth Curran of GameTek; Ocean Software designers Ray Coffey, James Higgins and Dawn Drake. Directed by Christopher Rawlence, produced by Debra Hauer, made by Rawlence Hauer Productions 13 December The Elements, a repeat of the 20 October 1991 episode 20 December E.T. Please Phone Earth, about the SETI Institute, with Prof Philip Morrison, a professor of physics at MIT, who played a starring if not dangerous role in the Manhattan Project; Jill Tarter at the Hat Creek Radio Observatory in California; Dr John Billingham, a British medical doctor at the Ames Research Center in California; Prof Antony Hewish of the University of Cambridge, who discovered pulsars in 1967; Frank Drake, and his work at the National Radio Astronomy Observatory in Green Bank, West Virginia; Barney Oliver of SETI; David Blair of the University of Western Australia; Paul Horowitz of Harvard University; the Ohio State University Radio Observatory (known as Big Ear) and its 1977 Wow! signal; Jack Cohen; chemist Stanley Miller and his 1953 experiment; blind SETI investigator Kent Cullers; and biologist Jared Diamond from UCLA. Jointly made with ABC of Australia, narrated by Heather Couper, directed by Richard Smith, produced by Stuart Carter, made by Pioneer Productions
Sources: en.wikipedia.org
The formyl peptide receptors (FPR) belong to a class of G protein-coupled receptors involved in chemotaxis. In humans, there are three formyl peptide receptor isoforms, each encoded by a separate gene that are named FPR1, FPR2, and FPR3. These receptors were originally identified by their ability to bind N-formyl peptides such as N-formylmethionine produced by the degradation of either bacterial or host cells. Hence formyl peptide receptors are involved in mediating immune cell response to infection. These receptors may also act to suppress the immune system under certain conditions. The close phylogenetic relation of signaling in chemotaxis and olfaction was recently proved by detection formyl peptide receptor like proteins as a distinct family of vomeronasal organ chemosensors in mice. FPR is now properly accepted as termed FPR1 by the International Union of Basic and Clinical Pharmacology.
=== Brand names === Buprenorphine is available under the brand names Cizdol, Brixadi (approved in the US by FDA for addiction treatment in 2023), Suboxone (with naloxone), Subutex (typically used for opioid use disorder), Zubsolv, Bunavail, Buvidal (approved in the UK, Europe and Australia for addiction treatment in 2018), Sublocade (approved in the US in 2018), Probuphine, Temgesic (sublingual tablets for moderate to severe pain), Buprenex (solutions for injection often used for acute pain in primary-care settings), Norspan, and Butrans (transdermal preparations used for chronic pain). In Poland buprenorphine is available under the trade names Bunondol (for pain treatment, when morphine is too little; amounts of 0.2 mg and 0.4 mg) and Bunorfin (for addicts substitution in amount of 2 and 8 mg).
=== Sublingual administration === Testosterone can be used by sublingual administration. A 10 mg sublingual tablet with the brand name Testoral was previously marketed for use one to four times per day in men.
A polyprotic acid is a compound which may lose more than 1 proton. Stepwise dissociation constants are each defined for the loss of a single proton. The constant for dissociation of the first proton may be denoted as Ka1 and the constants for dissociation of successive protons as Ka2, etc. Phosphoric acid, H3PO4, is an example of a polyprotic acid as it can lose three protons.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.